New drug DS1025a takes on advanced solid tumors in first human trial
NCT ID NCT07681882
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any signs of shrinking tumors. This is the first time DS1025a is being tested in humans, so it is a small, early-stage study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DS1025a
What this could lead to
If safe and effective, DS1025a could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early, small phase 1 trial focused on safety, so it is unknown if DS1025a will effectively shrink tumors or improve survival. Side effects are possible and will be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- SLC-3010 for Advanced Solid Tumors Trial NCT05525247
- BiCAP: Continued Access to Bicycle Therapies for NCT07681674
- GFH276 Combo for RAS-Mutant Solid Tumors & PDAC NCT07678593
- ON-TARGET: Palliative Care & Remote Monitoring f NCT07674797
- SHR-4685 for Solid Tumors Phase 1 Trial NCT07676903
- Long-Term Safety Study of Gotistobart for Advanc NCT07659379
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kansai Medical University Hospital
Osaka, 573-1191, Japan
Contact
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
Contact
-
The Cancer Institute Hospital of JFCR
Tokyo, 135-8550, Japan
Contact